ACXP net incomeQ2 2026-$2.25M
ACXP net income was -$2.25M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.25M a year earlier. For the full fiscal 2025 it was -$7.97M, compared with -$14.10M in fiscal 2024.
Acurx Pharmaceuticals Inc. (ACXP) financials
For the twelve months ended Jun 30, 2026, Acurx Pharmaceuticals Inc. reported -$7.51M of net income.
- Net income, TTM
- -$7.51M
- Cash
- $10.66M
- Market cap
- $5.9M
FY2020FY2025
ACXP revenue and earnings growth
ACXP EPSQ2 2026-$0.53
ACXP diluted EPS was -$0.53 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$5.32.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $1.83M | $5.40M | $6.04M | $4.75M | $2.03M | $2.20M |
| Selling, general and admin | $6.26M | $8.72M | $8.53M | $7.34M | $10.78M | $2.40M |
| Operating income | -$8.09M | -$14.12M | - | - | - | - |
| Income tax | - | - | - | $0 | - | $0 |
| Net income | -$7.97M | -$14.10M | -$14.58M | -$12.09M | -$12.75M | -$4.60M |
| EPS, basic | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| EPS, diluted | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| Diluted shares | 1.5M | 808,168 | 633,578.6 | 540,820.6 | 426,793.65 | 309,543.75 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $7.56M | $3.71M | $7.47M | $9.11M | $12.96M | $3.18M |
| Current assets | - | $3.86M | $7.71M | $9.38M | $13.25M | - |
| Total assets | $7.69M | $3.86M | $7.71M | $9.38M | $13.25M | $3.22M |
| Current liabilities | $2.42M | $3.24M | $3.04M | $2.06M | $843.9K | $472.6K |
| Total liabilities | $2.42M | $3.24M | $3.04M | $2.06M | $843.9K | $522.4K |
| Shareholders' equity | $5.27M | $615.1K | $4.67M | $7.32M | $12.41M | $2.70M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.79M | -$10.38M | -$9.80M | -$7.54M | -$5.01M | -$3.35M |
| Financing cash flow | $10.64M | $6.62M | $8.16M | $3.70M | $14.80M | $4.04M |
| Stock-based compensation | $1.25M | $2.60M | $3.21M | $2.87M | $5.15M | $695.8K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.07M | $341.5K | $281.8K | $429.7K | $524.2K | $598.8K | $825.1K | $1.20M | $1.83M | $1.56M | $1.94M | $1.35M |
| Selling, general and admin | $1.24M | $1.37M | $1.34M | $1.60M | $1.75M | $1.58M | $1.97M | $1.63M | $2.30M | $2.82M | $3.17M | $1.77M |
| Operating income | -$2.31M | -$1.72M | -$1.62M | -$2.03M | -$2.27M | -$2.18M | -$2.79M | -$2.83M | -$4.12M | -$4.38M | - | - |
| Net income | -$2.25M | -$1.68M | -$1.58M | -$1.99M | -$2.25M | -$2.15M | -$2.78M | -$2.82M | -$4.12M | -$4.38M | -$5.11M | -$3.11M |
| EPS, basic | -$0.53 | -$0.62 | - | -$1.23 | -$1.89 | -$2.15 | -$3.19 | -$3.45 | -$5.21 | -$5.60 | -$7.60 | -$4.80 |
| EPS, diluted | -$0.53 | -$0.62 | - | -$1.23 | -$1.89 | -$2.15 | -$3.19 | -$3.45 | -$5.21 | -$5.60 | -$7.60 | -$4.80 |
| Diluted shares | 4.3M | 2.7M | - | 1.6M | 1.2M | 1.0M | - | 818,174 | 791,233 | 773,625.35 | - | 650,256.4 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.66M | $9.25M | $7.56M | $5.91M | $6.06M | $4.64M | $3.71M | $5.76M | $6.36M | $8.92M | $7.47M | $7.05M |
| Current assets | - | - | - | - | $6.16M | $4.81M | $3.86M | $5.98M | - | - | $7.71M | $7.16M |
| Total assets | $10.98M | $9.54M | $7.69M | $6.11M | - | - | $3.86M | - | $6.58M | $9.11M | $7.71M | - |
| Current liabilities | $2.83M | $2.53M | $2.42M | $2.47M | $2.59M | $2.49M | $3.24M | $3.32M | $3.15M | $3.11M | $3.04M | $3.22M |
| Total liabilities | $2.83M | $2.53M | $2.42M | $2.47M | $2.59M | $2.49M | $3.24M | $3.32M | $3.15M | $3.11M | $3.04M | $3.22M |
| Shareholders' equity | $8.15M | $7.01M | $5.27M | $3.64M | $3.57M | $2.31M | $615.1K | $2.66M | $3.43M | $6.00M | $4.67M | $3.93M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.71M | -$1.41M | -$1.18M | -$1.88M | -$1.67M | -$2.05M | -$2.25M | -$2.19M | -$2.88M | -$3.06M | -$4.20M | -$2.09M |
| Financing cash flow | $3.11M | $3.11M | $2.83M | $1.72M | $3.09M | $2.99M | $194.5K | $1.59M | $320.2K | $4.51M | $4.62M | $0 |
| Stock-based compensation | $200.5K | $258.3K | $294.8K | $294.8K | $324.2K | $333.6K | $345.2K | $345.2K | $1.02M | $894.5K | $833.3K | $833.3K |
Key ratios
Source: XBRL data Acurx Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 11, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ACXP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ACXP | - | - | -$7.51M | - | $5.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
ACXP FAQ
4 questionsIs ACXP profitable?
No. Acurx Pharmaceuticals Inc. reported a net loss of $7.51M for the twelve months ended Jun 30, 2026.How much cash and debt does ACXP have?
Acurx Pharmaceuticals Inc. reported $10.66M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did ACXP last report financial results?
The latest statements here come from Acurx Pharmaceuticals Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this ACXP financial data come from?
Quantisnow builds these statements from the structured XBRL data Acurx Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.